Evidence map›Paper›PMID 36056985›Full record

ArticleBrain informatics2022

A multi-expert ensemble system for predicting Alzheimer transition using clinical features.

Mario Merone, Sebastian Luca D'Addario, Pierandrea Mirino, Francesca Bertino, Cecilia Guariglia, Rossella Ventura, Adriano Capirchio, Gianluca Baldassarre, Massimo Silvetti, Daniele Caligiore

Open access · goldAbstract read
In one paragraph

Article in Brain informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Mario MeroneUnit of Computer Systems and Bioinformatics, Department of Engineering, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128, Rome, Italy.
Sebastian Luca D'AddarioDepartment of Psychology, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Pierandrea MirinoDepartment of Psychology, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Francesca BertinoComputational and Translational Neuroscience Laboratory, Institute of Cognitive Sciences and Technologies, National Research Council (CTNLab-ISTC-CNR), Via San Martino della Battaglia 44, 00185, Rome, Italy.
Cecilia GuarigliaDepartment of Psychology, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Rossella VenturaDepartment of Psychology, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Adriano CapirchioAI2Life s.r.l., Innovative Start-Up, ISTC-CNR Spin-Off, Via Sebino 32, 00199, Rome, Italy.
Gianluca BaldassarreAI2Life s.r.l., Innovative Start-Up, ISTC-CNR Spin-Off, Via Sebino 32, 00199, Rome, Italy.
Massimo SilvettiComputational and Translational Neuroscience Laboratory, Institute of Cognitive Sciences and Technologies, National Research Council (CTNLab-ISTC-CNR), Via San Martino della Battaglia 44, 00185, Rome, Italy.
Daniele CaligioreComputational and Translational Neuroscience Laboratory, Institute of Cognitive Sciences and Technologies, National Research Council (CTNLab-ISTC-CNR), Via San Martino della Battaglia 44, 00185, Rome, Italy. daniele.caligiore@istc.cnr.it.
Institute of Cognitive Sciences and Technologies · ITFondazione Santa Lucia · ITSapienza University of Rome · ITSuperconducting and other Innovative Materials and Devices Institute · ITUniversità Campus Bio-Medico · IT

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Alzheimer's disease (AD) diagnosis often requires invasive examinations (e.g., liquor analyses), expensive tools (e.g., brain imaging) and highly specialized personnel. The diagnosis commonly is established when the disorder has already caused severe brain damage, and the clinical signs begin to be apparent. Instead, accessible and low-cost approaches for early identification of subjects at high risk for developing AD years before they show overt symptoms are fundamental to provide a critical time window for more effective clinical management, treatment, and care planning. This article proposes an ensemble-based machine learning algorithm for predicting AD development within 9 years from first overt signs and using just five clinical features that are easily detectable with neuropsychological tests. The validation of the system involved both healthy individuals and mild cognitive impairment (MCI) patients drawn from the ADNI open dataset, at variance with previous studies that considered only MCI. The system shows higher levels of balanced accuracy, negative predictive value, and specificity than other similar solutions. These results represent a further important step to build a preventive fast-screening machine-learning-based tool to be used as a part of routine healthcare screenings.

Indexed as

ADAS scoreCerebellar impairmentClinical Dementia Rating ScaleEarly diagnosisMachine learningRenal and genitourinary dysfunctions

Identifiers

PMID36056985
PMCPMC9440971
OpenAlexW4294433650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.